Massachusetts Financial Services Co. MA Makes New $12.34 Million Investment in Viking Therapeutics, Inc. (NASDAQ:VKTX)

Massachusetts Financial Services Co. MA acquired a new stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTXFree Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 663,155 shares of the biotechnology company’s stock, valued at approximately $12,341,000. Massachusetts Financial Services Co. MA owned approximately 0.66% of Viking Therapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. New York State Common Retirement Fund grew its position in Viking Therapeutics by 1.6% during the 4th quarter. New York State Common Retirement Fund now owns 39,321 shares of the biotechnology company’s stock worth $732,000 after purchasing an additional 609 shares during the last quarter. Pallas Capital Advisors LLC lifted its stake in shares of Viking Therapeutics by 6.8% during the fourth quarter. Pallas Capital Advisors LLC now owns 14,366 shares of the biotechnology company’s stock worth $267,000 after buying an additional 917 shares during the period. Knights of Columbus Asset Advisors LLC grew its holdings in shares of Viking Therapeutics by 3.1% during the third quarter. Knights of Columbus Asset Advisors LLC now owns 40,557 shares of the biotechnology company’s stock valued at $449,000 after buying an additional 1,226 shares during the last quarter. Quantum Private Wealth LLC increased its position in shares of Viking Therapeutics by 2.0% in the 3rd quarter. Quantum Private Wealth LLC now owns 66,650 shares of the biotechnology company’s stock valued at $738,000 after acquiring an additional 1,300 shares during the period. Finally, Wetzel Investment Advisors Inc. acquired a new position in shares of Viking Therapeutics in the 4th quarter valued at $37,000. 76.03% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, COO Marianna Mancini sold 281,425 shares of Viking Therapeutics stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $78.66, for a total value of $22,136,890.50. Following the sale, the chief operating officer now owns 348,508 shares of the company’s stock, valued at approximately $27,413,639.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CFO Greg Zante sold 66,756 shares of the company’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $74.69, for a total transaction of $4,986,005.64. Following the completion of the transaction, the chief financial officer now owns 174,854 shares in the company, valued at approximately $13,059,845.26. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Marianna Mancini sold 281,425 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $78.66, for a total transaction of $22,136,890.50. Following the completion of the transaction, the chief operating officer now directly owns 348,508 shares in the company, valued at $27,413,639.28. The disclosure for this sale can be found here. 4.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

VKTX has been the subject of a number of research reports. Maxim Group reaffirmed a “buy” rating and set a $120.00 price target on shares of Viking Therapeutics in a research report on Friday, March 15th. StockNews.com upgraded Viking Therapeutics to a “sell” rating in a research report on Friday. Truist Financial reiterated a “buy” rating and issued a $120.00 price target on shares of Viking Therapeutics in a report on Thursday. Jefferies Financial Group assumed coverage on shares of Viking Therapeutics in a research note on Thursday, March 7th. They set a “buy” rating and a $110.00 price objective for the company. Finally, Raymond James upgraded shares of Viking Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their price objective for the stock from $115.00 to $116.00 in a research note on Thursday. One investment analyst has rated the stock with a sell rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Viking Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $112.38.

Check Out Our Latest Analysis on VKTX

Viking Therapeutics Price Performance

Shares of NASDAQ VKTX opened at $67.00 on Friday. The company’s fifty day moving average price is $72.27 and its 200 day moving average price is $42.24. Viking Therapeutics, Inc. has a 1 year low of $8.28 and a 1 year high of $99.41.

Viking Therapeutics (NASDAQ:VKTXGet Free Report) last issued its quarterly earnings data on Wednesday, April 24th. The biotechnology company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.01. During the same quarter last year, the company posted ($0.25) earnings per share. As a group, analysts anticipate that Viking Therapeutics, Inc. will post -1.08 earnings per share for the current year.

Viking Therapeutics Company Profile

(Free Report)

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

Recommended Stories

Institutional Ownership by Quarter for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.